Congress clears CDER reorganization aimed at deepening FDA therapeutic expertise

Congress has signed off on an FDA reorganization that is intended to allow drug reviewers to develop greater expertise in both the diseases that are being treated and the technologies underlying new medicines.

The changes will create more senior positions

Read the full 405 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE